

Hepatocellular adenoma: different entities for a single lesion

Pierre Bedossa

Department of Pathology, Hôpital Beaujon, University Paris Diderot, France.

A 28-year-old female presented with upper quadrant abdominal pain. The patient did use oral contraceptives, her BMI was 35 kg/m² and serum AFP level was within normal limit. A palpable liver mass was noted and CT demonstrated a pedunculated 10 cm tumor under the right liver lobe. A resection was performed.

Image: The resected specimen showed a solitary well-circumscribed but not encapsulated tumor (Figure 1A). On light microscope, the tumor was made of normal hepatocytes organized in trabeculae often dissociated by dilated sinusoids (Figure 1B). No portal tract or central vein was noted within

the tumor. Small aggregates made of unpaired arteries embedded by collagen fibers and inflammatory cells, mainly lymphocytes were present within the tumor (Figure 1C). Hepatocytes display a strong immunostaining with anti-SAA antibody (Figure 1D). No dysplastic or tumoral area was noted within the tumor. The peritumoral liver was normal.

Diagnosis: telangiectatic/inflammatory hepatocellular adenoma.

Hepatocellular adenoma (HCA) is a rare, benign liver neoplasm strongly associated with use of oral contraceptive (OC) in females, androgen steroid




Figure 1. The resected specimen showed a solitary well-circumscribed but not encapsulated tumor (A). On light microscope (B and C) and immunostaining with anti-SAA antibody (D).

therapy in male or with rare genetic metabolic diseases.¹ HCAs are usually solitary, well-delineated, sometimes encapsulated, with a fleshy appearance. Histologically, HCA consists of a proliferation of benign hepatocytes arranged in a trabecular pattern, without any residual lobular organisation. Small thin and unpaired vessels are usually found throughout the tumor.

Molecular studies have recently gained insights in the physiopathology of HCA resulting in the categorization of HCA into 3 main subtypes with specific histological and molecular features.² These molecular alterations allowed to develop specific immunohistochemical markers for each tumor type that can be used as surrogate of molecular testing.³

The first group of HCA displays biallelic mutations of the *TCF1* gene inactivating the hepatocyte nuclear factor 1 α (HNF1 α) transcription factor.⁴ Histologically, it is characterized by marked steatosis, absence of cytological abnormalities or inflammatory infiltrates. Whereas, HNF1 α mutations are somatic in most cases, patients with inherited mutation in one allele of HNF1 α may develop maturity-onset diabetes of the young type 3 (MODY3) and are predisposed to have familial liver adenomatosis when the second allele is inactivated. Lack of Liver Fatty Acid Binding Protein (LFABP) expression, a protein positively regulated by HNF1 α , serve as surrogate for characterization of HNF1 α -mutated HCA by immunohistochemistry.

The second group of HCA displays β -catenin-activating mutations and is characterized by increased risk for malignant transformation into HCC. These HCA are mostly encountered in male patients and frequently show significant cell atypias and pseudoglandular formations.² This HCA subtype display abnormal nuclear staining of β -catenin in tumoral hepatocytes and a strong cytoplasmic immunostaining with glutamine synthetase, a β -catenin-targeted gene.

The third group of HCA is the telangiectatic/inflammatory adenoma subgroup characterized by sinusoidal dilation and/or peliotic changes, the presence of few and short fibrous tracts around small arteries, sometimes accompanied by inflammatory infiltrates.⁵ These HCA are more frequent in

patients with overweight and with inflammatory syndrome. Indeed, inflammatory HCA display positive immunostaining with acute phase inflammatory proteins such as serum amyloid A (SAA) and CRP. In approximately 60% of these HCA, IL6 signaling pathway is activated in relation with mutations in the *IL6ST* gene that encodes the signaling co-receptor gp130.⁶

Lastly, β -catenin mutations may be observed in some telangiectatic/inflammatory HCA whereas gp130 activation and HNF1 α inactivation (steatotic subtype) are mutually exclusive. Finally, a small group of HCA remain "unclassified" since they do not display any specific morphological or genotypical features.

Due to the potential risk for complications (haemorrhage, malignant degeneration), surgical resection is required for HCA larger than 5 cm in diameter and for all HCAs in males whatever their size. Small lesions with a low risk of complication could be initially observed after cessation of OC.⁷

REFERENCES

1. Nime F, Pickren JW, Vana J, Aronoff BL, Baker HW, Murphy GP. The histology of liver tumors in oral contraceptive users observed during a national survey by the American College of Surgeons Commission on Cancer. *Cancer* 1979; 44: 1481-9.
2. Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. *Hepatology* 2006; 43: 515-24.
3. Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, Laurent C, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. *Hepatology* 2009; 50: 481-9.
4. Bluteau O, Jeannot E, Bioulac-Sage P, Marqués JM, Blanc JF, Bui H, Beaudoin JC, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. *Nat Genet* 2002; 32: 312-5.
5. Paradis V1, Champault A, Ronot M, Deschamps L, Valla DC, Vidaud D, Vilgrain V, et al. Telangiectatic adenomas: an entity associated with increased body mass index and inflammation. *Hepatology* 2007; 46:140-6.
6. Rebouissou S1, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, Izard T, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumors. *Nature* 2009; 457: 2000-4.
7. Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, Valla D, Bedossa P, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. *Gastroenterology* 2009; 137: 1698-705.